Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HLA-DR is a procoagulant.

M Chelladurai1, K V Honn, D A Walz

  • 1Department of Radiation Oncology, Wayne State University, Detroit, MI.

Biochemical and Biophysical Research Communications
|July 31, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiosensitivity of human prostate cancer cells can be modulated by inhibition of 12-lipoxygenase.

Cancer letters·2013
Same author

Cyclooxygenase, lipoxygenase and tumor angiogenesis.

Cellular and molecular life sciences : CMLS·2002
Same author

Role of eicosanoids in prostate cancer progression.

Cancer metastasis reviews·2002
Same author

Molecular markers in Paget disease of the breast.

Journal of surgical oncology·2001
Same author

Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase- and PKC-mediated serine phosphorylation events in melanoma cells.

Thrombosis and haemostasis·2001
Same author

Interferon alpha2b inhibits the murine melanoma cell line Cloudman S91 in vivo but not in vitro: a model for studying tumor cell-cytokine interactions.

The American surgeon·2001

Major histocompatibility antigen HLA-DR, found in ovarian cancer, promotes blood clotting. Staphylococcal enterotoxin A inhibits this activity, offering potential therapeutic strategies for cancer and transplant patients.

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • Thromboembolic complications are frequent in cancer patients and organ transplant recipients.
  • Tumor procoagulants are linked to cancer metastasis.
  • Human ovarian carcinoma contains proteins with procoagulant activity.

Purpose of the Study:

  • To investigate the procoagulant activity of proteins isolated from human ovarian carcinoma.
  • To identify the specific protein responsible for procoagulant activity and its relation to major histocompatibility antigen HLA-DR.
  • To explore the therapeutic potential of inhibiting this procoagulant activity.

Main Methods:

  • Isolation and characterization of protein bands from ovarian carcinoma.
  • Amino terminal sequencing to identify protein identity.

Related Experiment Videos

  • Immunoaffinity column chromatography using monoclonal antibody to HLA-DR.
  • Assay of thrombin generation in plasma.
  • Inhibition studies using Staphylococcal enterotoxin A.

    • Main Results:

    • Two protein bands (35,000 and 28,000 daltons) with procoagulant activity were isolated.
    • The 35,000 dalton protein's amino terminal sequence matched HLA-DR.
    • Immunoaffinity purification of HLA-DR yielded procoagulant activity.
    • Purified HLA-DR enhanced thrombin generation approximately 20-fold.
    • Staphylococcal enterotoxin A completely inhibited HLA-DR procoagulant activity.

    Conclusions:

    • The procoagulant nature of HLA-DR may contribute to thrombotic disorders in cancers and graft rejection.
    • Inhibition of HLA-DR procoagulant activity by enterotoxin A presents a potential therapeutic strategy.